This site is intended for UK-registered healthcare professionals only
Media partners:
Prescribing Information and adverse events reporting information can be found at the bottom of this page.
This website has been developed and funded by A. Menarini Farmaceutica Internazionale SRL. The Improving Diabetes Steering Committee is supported by A. Menarini Farmaceutica Internazionale SRL. The SGLT2 Inhibitor Prescribing Decision Tool has been independently prepared by the IDSC. The media partners for this activity are GPnotebook and Diabetes on the net. GPnotebook and Diabetes on the net have had no input into the content of this website.
Use our evidence-led, interactive SGLT2 Inhibitor Prescribing Decision Tool for a quick reference guide that supports you in making appropriate prescribing decisions in clinical practice.
The handy traffic light system provides clarity regarding common areas of confusion, including the early and late use of SGLT2 inhibitors and complication risk.
The SGLT2 Inhibitor Prescribing Decision Tool has been independently prepared by the IDSC. A. Menarini Farmaceutica Internazionale SRL has fully funded the development of the SGLT2 Inhibitor Prescribing Decision Tool wallchart.
Do you know how to optimally treat a young patient with type 2 diabetes who has an increased risk of developing cardiovascular and/or renal disease, but their HbA1c is normal?
Are you confident in managing comorbid patients who deal with type 2 diabetes and chronic kidney disease or diabetic polyneuropathy?
The IDSC have put together a list of detailed case studies which you might come across in your practice. Access these below to increase your confidence in managing your patients.
The clinical case studies are fictitious and are for guidance only.
The IDSC has published five narrative reviews1–5 that reflect the growing evidence surrounding SGLT2 inhibitors in type 2 diabetes and aim to translate these evidence into clinical practice.
The most recent narrative review5 summarises the value of SGLT2 inhibitors in treating cardiovascular, renal and metabolic diseases, and places the relative risks into context.
The IDSC has published five narrative reviews1–5 that reflect the growing evidence surrounding SGLT2 inhibitors in type 2 diabetes and aim to translate this evidence into clinical practice.
The most recent narrative review5 summarises the value of SGLT2 inhibitors in treating CVRM diseases, and places the relative risks into context.
The above link will direct you to a third-party website. A. Menarini Farmaceutica Internazionale SRL and the media partners have had no input into the content of this website.
CVRM: cardiovascular, renal and metabolic; IDSC: Improving Diabetes Steering Committee; SGLT2: sodium-glucose co-transporter-2
Watch Professor David Wheeler and Jane Diggle walk through the practicalities of the SGLT2 Inhibitor Prescribing Decision Tool for type 2 diabetes management and how you can access the IDSC resources.
Join Lisa Kelly as she interviews Professor John Wilding on his role in the IDSC, their previous and most recent outputs, and how the materials they produce aim to benefit both healthcare professionals and people living with type 2 diabetes.
Watch Lisa Kelly and Phillip Newland-Jones discuss the importance of concomitant treatment in diabetes and other cardiorenal metabolic diseases, and how the tools developed by the IDSC can help both healthcare professionals and patients with type 2 diabetes.
Hear Lisa Kelly and Professor David Wheeler discuss the latest guideline-based narrative review by the IDSC, and the link between diabetes and kidney disease.
Watch Dr Kevin Fernando talk about the impact the IDSC has had over the past six years – from five narrative reviews to evidence- and guideline-based prescribing decision tools.
Jane Diggle discusses her involvement with the IDSC, and the outputs and impact this interdisciplinary expert group has had in the diabetes landscape.
CVRM: cardiovascular, renal and metabolic; IDSC: Improving Diabetes Steering Committee; SGLT2: sodium-glucose co-transporter-2
References
Invokana® (canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, please refer to section 4.4, 4.5 and 5.1 of the Invokana SmPC.
Click here for Invokana® (canagliflozin) United Kingdom Prescribing Information.
This website has been developed and funded by A. Menarini Farmaceutica Internazionale SRL. The Improving Diabetes Steering Committee is supported by A. Menarini Farmaceutica Internazionale SRL. The SGLT2 Inhibitor Prescribing Decision Tool has been independently prepared by the IDSC. The media partners for this activity are GPnotebook and Diabetes on the net. GPnotebook and Diabetes on the net have had no input into the content of this website.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL on 0800 085 8678 or by e-mail: [email protected]
PP-IN-UK-1449 v2 | November 2025
A. Menarini Farmaceutica Internazionale SRL have had no input into the contents of the footer and are not affiliated with the links. GPnotebook is responsible for the contents of the footer.
To continue, please confirm that you are a UK-registered healthcare professional by clicking one of the buttons below